SE9302135D0 - New pharmaceutical composition - Google Patents
New pharmaceutical compositionInfo
- Publication number
- SE9302135D0 SE9302135D0 SE19939302135A SE9302135A SE9302135D0 SE 9302135 D0 SE9302135 D0 SE 9302135D0 SE 19939302135 A SE19939302135 A SE 19939302135A SE 9302135 A SE9302135 A SE 9302135A SE 9302135 D0 SE9302135 D0 SE 9302135D0
- Authority
- SE
- Sweden
- Prior art keywords
- pct
- administration
- sec
- compositions
- date
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE19939302135A SE9302135D0 (sv) | 1993-06-18 | 1993-06-18 | New pharmaceutical composition |
DE69429169T DE69429169T2 (de) | 1993-06-18 | 1994-06-16 | Pharmazeutisches präparat, das heparin, heparinfragmente oder -derivate in kombination mit glycerinestern enthält |
DK94919936T DK0706398T3 (da) | 1993-06-18 | 1994-06-16 | Farmaceutisk sammensætning indeholdende heparin, heparinfragmenter eller derivater heraf i kombination med glycerolestere |
ES94919936T ES2168299T3 (es) | 1993-06-18 | 1994-06-16 | Composicion farmaceutica que contiene heparina, fragmentos de heparina o sus derivados en combinacion con esteres de glicerol. |
US08/569,087 US5714477A (en) | 1993-06-18 | 1994-06-16 | Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters |
EP94919936A EP0706398B1 (de) | 1993-06-18 | 1994-06-16 | Pharmazeutisches präparat, das heparin, heparinfragmente oder -derivate in kombination mit glycerinestern enthält |
PCT/SE1994/000595 WO1995000152A1 (en) | 1993-06-18 | 1994-06-16 | Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters |
AT94919936T ATE209038T1 (de) | 1993-06-18 | 1994-06-16 | Pharmazeutisches präparat, das heparin, heparinfragmente oder -derivate in kombination mit glycerinestern enthält |
JP50271195A JP3953510B2 (ja) | 1993-06-18 | 1994-06-16 | 医薬組成物 |
PT94919936T PT706398E (pt) | 1993-06-18 | 1994-06-16 | Composicao farmaceutica contendo heparina fragmentos de heparina ou seus derivados em combinacao com esteres de glicerol |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE19939302135A SE9302135D0 (sv) | 1993-06-18 | 1993-06-18 | New pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9302135D0 true SE9302135D0 (sv) | 1993-06-18 |
Family
ID=20390356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE19939302135A SE9302135D0 (sv) | 1993-06-18 | 1993-06-18 | New pharmaceutical composition |
Country Status (10)
Country | Link |
---|---|
US (1) | US5714477A (de) |
EP (1) | EP0706398B1 (de) |
JP (1) | JP3953510B2 (de) |
AT (1) | ATE209038T1 (de) |
DE (1) | DE69429169T2 (de) |
DK (1) | DK0706398T3 (de) |
ES (1) | ES2168299T3 (de) |
PT (1) | PT706398E (de) |
SE (1) | SE9302135D0 (de) |
WO (1) | WO1995000152A1 (de) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6008228A (en) * | 1995-06-06 | 1999-12-28 | Hoffman-La Roche Inc. | Pharmaceutical compositions containing proteinase inhibitors |
SE9602145D0 (sv) | 1996-05-31 | 1996-05-31 | Astra Ab | New improved formulation for treatment of thromboembolism |
US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US6458383B2 (en) | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
US6982281B1 (en) * | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
CA2377734A1 (en) * | 1999-06-30 | 2001-01-11 | Hamilton Civic Hospitals Research Development, Inc. | Heparin compositions that inhibit clot associated coagulation factors |
EP1251867A4 (de) | 2000-02-04 | 2004-12-08 | Unigene Lab Inc | Nasale calcitoninformulierungen |
DE10026699A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage |
BR0113886A (pt) * | 2000-09-08 | 2003-07-15 | Hamilton Civic Hospitals Res | Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit |
WO2002092069A1 (en) * | 2001-05-11 | 2002-11-21 | Elan Corporation, Plc | Permeation enhancers |
JP2004529953A (ja) * | 2001-05-11 | 2004-09-30 | エラン コーポレーシヨン ピーエルシー | 浸透促進剤としてのイソステアリン酸塩 |
JP4317010B2 (ja) * | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | IgG抗体の安定な凍結乾燥医薬製剤 |
SE521676C2 (sv) * | 2002-01-02 | 2003-11-25 | Dilafor Ab | Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet |
AU2003230985A1 (en) * | 2002-04-18 | 2003-11-03 | Stephen H. Embury | Method and composition for preventing pain in sickle cell patients |
US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
CN101084016A (zh) * | 2004-04-15 | 2007-12-05 | 克艾思马有限公司 | 能够容易穿透生物学障碍的组合物 |
US20070219131A1 (en) * | 2004-04-15 | 2007-09-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
NZ550894A (en) * | 2004-05-06 | 2011-02-25 | Emisphere Tech Inc | Solid dosage form of wetted heparin |
WO2005112633A2 (en) | 2004-05-14 | 2005-12-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US20050282775A1 (en) * | 2004-06-16 | 2005-12-22 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome |
US7563780B1 (en) * | 2004-06-18 | 2009-07-21 | Advanced Cardiovascular Systems, Inc. | Heparin prodrugs and drug delivery stents formed therefrom |
CN101583273A (zh) * | 2005-07-22 | 2009-11-18 | 加利福尼亚大学董事会 | 肝素组合物和选择素抑制 |
US20070154546A1 (en) * | 2005-12-30 | 2007-07-05 | Zhang Jack Y | Sustained release pharmaceutical compositions |
BRPI0710503A2 (pt) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
US20070292512A1 (en) * | 2006-06-09 | 2007-12-20 | Merrion Research Ii Limited | Solid Oral Dosage Form Containing an Enhancer |
CN102046192B (zh) * | 2008-05-07 | 2014-11-19 | 默里昂研究Ⅲ有限公司 | GnRH相关化合物的组合物及制备方法 |
CA2963659C (en) | 2008-09-17 | 2020-06-23 | Chiasma Inc. | Use of oral octreotride compositions |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
WO2010099255A1 (en) * | 2009-02-25 | 2010-09-02 | Merrion Research Iii Limited | Composition and drug delivery of bisphosphonates |
WO2011084618A2 (en) | 2009-12-16 | 2011-07-14 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
US20110142889A1 (en) * | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
CA2784529C (en) | 2009-12-18 | 2018-05-22 | Catalent France Beinheim Sa | Pharmaceutical oral dosage form containing a synthetic oligosaccharide |
US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
US9089484B2 (en) * | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
CN103476419A (zh) | 2011-01-07 | 2013-12-25 | 梅里翁第三研究有限公司 | 口服投药的含铁药物组合物 |
HUE053247T2 (hu) | 2012-05-09 | 2021-06-28 | Cantex Pharmaceuticals Inc | Mieloszuppresszió kezelése |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
CN107205948B (zh) | 2015-01-29 | 2021-12-14 | 诺和诺德股份有限公司 | 包含glp-1激动剂和肠溶衣的片剂 |
AU2016215350B2 (en) | 2015-02-03 | 2021-11-25 | Amryt Endo, Inc. | Method of treating diseases |
WO2016133910A1 (en) | 2015-02-17 | 2016-08-25 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
EP3544614A4 (de) | 2016-11-28 | 2020-08-05 | Lipocine Inc. | Orale testosteron-undecanoat-therapie |
EP3870155A4 (de) * | 2018-10-25 | 2023-08-09 | Zeenar Enterprises Pty Ltd | Zusammensetzung zur formung von flüssigkristallinen partikeln |
US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3510561A (en) * | 1965-05-20 | 1970-05-05 | Canada Packers Ltd | Sulfone-enhanced heparin absorption through mucous membranes |
JPS53107408A (en) * | 1977-02-28 | 1978-09-19 | Yamanouchi Pharmaceut Co Ltd | Micellar preparation for rectal infusion |
CA1136620A (en) * | 1979-01-08 | 1982-11-30 | Ulf P.F. Lindahl | Heparin fragments having selective anticoagulation activity |
EP0037943B1 (de) * | 1980-03-31 | 1985-08-14 | Teijin Limited | Pharmazeutische Zusammensetzung zur rektalen Verabreichung und daraus hergestellte Zäpfchen |
JPS6028972A (ja) * | 1983-06-29 | 1985-02-14 | Kyowa Hakko Kogyo Co Ltd | ジベンゾ[b,e]オキセピン誘導体 |
DE3331009A1 (de) * | 1983-08-27 | 1985-03-14 | Basf Ag, 6700 Ludwigshafen | Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat |
FR2616661B1 (fr) * | 1987-06-19 | 1991-06-07 | Doutremepuich Christian | Composition a base de mucopolysaccharides hepariniques, active par voie orale |
DE3805523A1 (de) * | 1988-02-22 | 1989-10-05 | Schur Pharmazeutika Gmbh & Co | Pharmazeutische praeparate zur transdermalen applikation von heparin |
-
1993
- 1993-06-18 SE SE19939302135A patent/SE9302135D0/xx unknown
-
1994
- 1994-06-16 US US08/569,087 patent/US5714477A/en not_active Expired - Fee Related
- 1994-06-16 JP JP50271195A patent/JP3953510B2/ja not_active Expired - Fee Related
- 1994-06-16 DK DK94919936T patent/DK0706398T3/da active
- 1994-06-16 ES ES94919936T patent/ES2168299T3/es not_active Expired - Lifetime
- 1994-06-16 AT AT94919936T patent/ATE209038T1/de not_active IP Right Cessation
- 1994-06-16 EP EP94919936A patent/EP0706398B1/de not_active Expired - Lifetime
- 1994-06-16 PT PT94919936T patent/PT706398E/pt unknown
- 1994-06-16 DE DE69429169T patent/DE69429169T2/de not_active Expired - Fee Related
- 1994-06-16 WO PCT/SE1994/000595 patent/WO1995000152A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
ATE209038T1 (de) | 2001-12-15 |
US5714477A (en) | 1998-02-03 |
ES2168299T3 (es) | 2002-06-16 |
JP3953510B2 (ja) | 2007-08-08 |
EP0706398B1 (de) | 2001-11-21 |
DE69429169D1 (de) | 2002-01-03 |
DE69429169T2 (de) | 2002-06-20 |
WO1995000152A1 (en) | 1995-01-05 |
JPH09501652A (ja) | 1997-02-18 |
EP0706398A1 (de) | 1996-04-17 |
DK0706398T3 (da) | 2002-05-21 |
PT706398E (pt) | 2002-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE9302135D0 (sv) | New pharmaceutical composition | |
NO963639D0 (no) | Sublingual eller buckal farmasöytisk blanding | |
EP1153924A3 (de) | Substutuierte 1,3-Oxathiolane mit antiviralen Eigenschaften | |
AU4884696A (en) | Pharmaceutical compositions comprising monoamine oxidase B inhibitors | |
DE69713300T2 (de) | Benzopyran derivate mit leukotrien-antagonistischer wirkung | |
DK0937060T3 (da) | Nye cis-3,4-chroman-derivater, der er nyttige i forebyggelsen eller behandlingen af østrogen-relaterede sygdomme eller syndromer | |
HK1023346A1 (en) | Novel substituted tetrahyropyridine derivatives, method of preparation and pharmaceutical compositions containing them | |
FI951277A (fi) | Uudet N,N,N',N'-tetrasubstituoituneet 1,2-etaanidiamiinijohdannaisyhdisteet | |
DK0937057T3 (da) | Hidtil ukendte (-)-enantiomerer af cis-3,4-chromanderivater anvendelige i forebyggelse eller behandling af østrogenrelaterede sygdomme eller syndromer | |
DK0937062T3 (da) | Nye cis-3,4-chroman-derivater, der er nyttige i forebyggelsen eller behandlingen af østrogen-relaterede sygdomme eller syndromer | |
CA2434775A1 (en) | Compounds for use in the treatment of skin conditions | |
DE59304476D1 (de) | Lagerstabile Lösungen von carbonisiertem Magnesiumethylat in Ethanol sowie deren Herstellung und Verwendung |